StockData

CG Oncology vs TScan Therapeutics

CGON and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CGON and TCRX compare

CG Oncology is the larger company, worth 764 times as much as TScan Therapeutics ($7.5B against $9.8M).

CG Oncology grew revenue faster over the last twelve months (184% versus 2.2% for TScan Therapeutics).

TScan Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1655% compared with −3851% at CG Oncology.

CG Oncology scores higher on the StockData Score (5 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCGONTCRX
Size and price
Market cap$7.5B$9.8M
Share price$84.78$0.145
Change, 1 year125%−87.2%
Change, 5 years–−98.3%
Beta (5Y)0.242.20
Employees142142
StockData Score
Total score5 (better)4
Valuation score03 (better)
Growth score1 (better)0
Performance score1 (better)0
Health score3 (better)1
Dividend score00
Valuation
P/S1219×1.4× (better)
P/B7.6×0.1× (better)
FCF yield−2.5% (better)−1204%
Fair value–$1.36
Margin of safety–89.3%
Growth
Revenue growth (TTM)184% (better)2.2%
Revenue growth, 5Y average–56.9%
Profitability
Operating margin−4294%−1695% (better)
Net margin−3851%−1655% (better)
FCF margin−3068%−1666% (better)
Return on equity−28.3% (better)−95.8%
Return on invested capital−2103%–
Financial health
Debt / equity0.00 (better)0.47
Interest coverage–−43.2×
Current ratio21.70 (better)3.37
Altman Z-score80.45 (better)−6.31
Piotroski F-score12 (better)
Dividends and buybacks
Buyback yield−6.5%–
Shareholder yield−6.5%0.00% (better)
Ownership
Held by institutions106%53.5%
Held by insiders17.3%32.8%
Insider net buying, 12 months$20.0M (better)$146K
Short interest, % of float12.6%4.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.